Asset
Vispacabtagene Regedleucel
Caribou Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04637763 | phase1 | unknown | 2021-05-26 | 2025-08-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) |
| NCT06752876 | phase1 | withdrawn | 2027-12-01 | 2029-04-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) |
FDA applications (0)
This company has no applications containing this asset.